The migraine market is expected to grow steadily over the forecast period (2026–2036) driven by the rising global prevalence of migraine, improving diagnosis rates, and increasing awareness of chronic and high-frequency migraine. In addition, the introduction of novel, differentiated therapies such as Elismetrep (Kallyope), Dysport (abobotulinumtoxinA; Ipsen), Xeomin (incobotulinumtoxinA; Merz Therapeutics GmbH), Bocunebart (AG09222; Lundbeck), EVO756 (Evommune), and others that move beyond traditional acute treatments is expected to further expand the market.
New York, USA, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight
The migraine market is expected to grow steadily over the forecast period (2026–2036) driven by the rising global prevalence of migraine, improving diagnosis rates, and increasing awareness of chronic and high-frequency migraine. In addition, the introduction of novel, differentiated therapies such as Elismetrep (Kallyope), Dysport (abobotulinumtoxinA; Ipsen), Xeomin (incobotulinumtoxinA; Merz Therapeutics GmbH), Bocunebart (AG09222; Lundbeck), EVO756 (Evommune), and others that move beyond traditional acute treatments is expected to further expand the market.
Recently published Migraine Market Insights report includes a comprehensive understanding of current treatment practices, migraine emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Migraine Market Summary
- The market size for migraine was found to be USD 8.3 billion in the 7MM in 2025.
- The United States accounted for the largest migraine treatment market size in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
- Migraine represents a substantial epidemiological burden across the 7MM, with adults accounting for the majority of prevalent cases, with 85 million cases in 2025, compared with the pediatric population with 7 million cases.
- Key migraine companies, including Kallyope, Ipsen, Merz Therapeutics GmbH, Lundbeck, Evommune, and others, are actively working on innovative migraine drugs.
- Some of the key migraine therapies in clinical trials include Elismetrep, Dysport (abobotulinumtoxinA), Xeomin (incobotulinumtoxinA), Bocunebart (AG09222), EVO756, and others. These novel migraine therapies are anticipated to enter the migraine market in the forecast period and are expected to change the market.
Discover more about the migraine therapeutic market @ https://www.delveinsight.com/report-store/migraine-market
Key Factors Driving the Growth of the Migraine Market
- Rising Prevalence of Migraine: The growing global burden of migraine, particularly among working-age adults, is increasing the demand for effective acute and preventive treatments. Greater recognition and diagnosis of migraine are also expanding the treated patient population.
- Growing Adoption of CGRP-Targeted Therapies: Calcitonin gene-related peptide (CGRP) antagonists and monoclonal antibodies have transformed migraine management by offering migraine-specific treatment options with improved efficacy and tolerability. Their increasing use in both acute and preventive care is supporting market expansion.
- Increasing Demand for Preventive Treatments: Patients experiencing frequent or debilitating migraine attacks are increasingly seeking preventive therapies to reduce attack frequency and improve quality of life. The availability of oral and injectable preventive options is broadening treatment choices.
- Advancements in Non-Oral Drug Delivery: Development of nasal sprays, subcutaneous injections, orally disintegrating formulations, and other non-oral delivery approaches is addressing the need for rapid and convenient migraine relief. These formulations can be particularly valuable for patients experiencing nausea or vomiting during attacks.
- Expansion of Novel Migraine Therapies: Pharmaceutical companies are investing in therapies such as Elismetrep (Kallyope), Dysport (abobotulinumtoxinA; Ipsen), Xeomin (incobotulinumtoxinA; Merz Therapeutics GmbH), Bocunebart (AG09222; Lundbeck), EVO756 (Evommune), and others with differentiated mechanisms, longer durations of action, and improved safety profiles. Continued clinical development across acute and preventive treatment segments is strengthening the migraine treatment pipeline.
Shikha Bhardwaj, Associate Consultant of Forecasting & Analytics at DelveInsight, said that emerging approaches include TRPM8 channel blockers, MRGPRX2 antagonists, anti-PACAP monoclonal antibodies, acetylcholine-targeting therapies, and next-generation serotonergic agents, expanding the therapeutic landscape beyond established CGRP-targeted treatments.
Migraine Market Analysis
- Historically, acute migraine treatment was largely centered on non-specific analgesics and NSAIDs, such as ibuprofen, naproxen, diclofenac, and acetylsalicylic acid.
- The introduction of triptans, beginning with sumatriptan (IMITREX) in 1992, established a new class of migraine-specific acute therapies.
- Over time, multiple triptans and non-oral formulations were developed to improve treatment onset, duration of action, and tolerability.
- Ergot derivatives, particularly dihydroergotamine, also represented an important treatment option before triptans became widely adopted.
- More recently, CGRP-targeted gepants, including ubrogepant, rimegepant, and zavegepant, have broadened the acute treatment landscape. Atogepant has further expanded the application of CGRP-targeted therapies across migraine management, including preventive treatment and the evolving acute-treatment landscape.
- Migraine prevention has similarly progressed from conventional therapies toward more targeted treatment approaches.
- OnabotulinumtoxinA (BOTOX) continues to be an established therapy for chronic migraine, while CGRP monoclonal antibodies such as erenumab, fremanezumab, galcanezumab, and eptinezumab have expanded preventive options for both episodic and chronic migraine.
- Overall, the treatment landscape is increasingly moving toward migraine-specific, CGRP-targeted, and more convenient therapies, supported by continued advances in formulations and expansion into additional indications.
- The current emerging migraine pipeline is predominantly focused on preventive therapies, with next-generation botulinum toxin approaches such as Dysport and incobotulinumtoxinA (Xeomin), as well as novel candidates including EVO756 and bocunebart (AG09222).
- In the acute treatment segment, elismetrep (K-304) represents one of the notable late-stage candidates, underscoring the relatively limited number of late-stage innovations currently advancing in the acute migraine treatment market.
Learn more about the migraine drug market overview 2026 @ US Migraine Drugs Market
Migraine Competitive Landscape
Some of the migraine medications under development include Elismetrep (Kallyope), Dysport (abobotulinumtoxinA; Ipsen), Xeomin (incobotulinumtoxinA; Merz Therapeutics GmbH), Bocunebart (AG09222; Lundbeck), EVO756 (Evommune), and others.
Kallyope’s Elismetrep (K-304) is an investigational, novel, orally administered Transient Receptor Potential Melastatin 8 (TRPM8) migraine-associated channel blocker (MACB) with high selectivity for TRPM8 migraine-associated channels over other TRP channels. Specifically developed to inhibit TRPM8 activity, elismetrep has demonstrated the potential to reduce migraine pain and associated symptoms. The therapy is currently in Phase III development.
Ipsen’s Dysport (abobotulinumtoxinA) is an injectable botulinum neurotoxin type A (BoNT-A) product derived from Clostridium bacteria. It works by inhibiting the transmission of nerve impulses, thereby reducing muscle contractions. Dysport is supplied as a lyophilized powder for injection.
Lundbeck’s Bocunebart (Lu AG09222), developed by Lundbeck, is an investigational monoclonal antibody (mAb) designed to bind to and inhibit pituitary adenylate cyclase-activating polypeptide (PACAP). PACAP has emerged as a neuropeptide involved in the pathophysiology of migraine, making it a potential novel therapeutic target for migraine treatment.
The anticipated launch of these emerging migraine therapies are poised to transform the Migraine market landscape in the coming years. As these cutting-edge migraine therapies continue to mature and gain regulatory approval, they are expected to reshape the migraine market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about the best CGRP for migraine, visit @ Migraine Therapeutic Market
Recent Developments in the Migraine Market
- In July 2026, Evommune announced the first patient was dosed in its Phase IIb clinical trial evaluating a potent, highly selective oral small molecule antagonist of MRGPRX2, EVO756, for the prophylactic treatment of migraine.
- In June 2026, Lundbeck announced the presentation of new eptinezumab-jjmr (VYEPTI) data at the American Headache Society’s (AHS) 68th Annual Scientific Meeting, in Orlando, Florida. The presentations shared findings from the INFUSE, DELIVER, SUNSET, and RESOLUTION trials, featuring real-world data and phase III clinical trial post-hoc analyses of VYEPTI and patient-reported outcomes on headache hours, brain fog and other cognitive symptoms, and dose escalation.
- In June 2026, Kallyope presented results from several clinical and preclinical studies that support the initiation of Phase III studies of elismetrep. The data were presented at the American Headache Society 68th Annual Scientific Meeting.
- In June 2026, Satsuma Pharmaceuticals announced that two abstracts highlighting findings from its clinical development program have been selected for presentation at the AHS 68th Annual Scientific Meeting.
- In June 2026, Axsome Therapeutics presented four posters at the AHS 68th Annual Scientific Meeting highlighting new SYMBRAVO data, including post hoc analyses from the Phase III MOMENTUM, MOVEMENT, and INTERCEPT trials, as well as a network meta-analysis comparing SYMBRAVO with gepants for the acute treatment of migraine.
- In April 2026, Kallyope presented results from a Phase IIb dose-ranging and proof of concept study of elismetrep. The data were reported during an oral presentation titled “TRPM8 Antagonism with Elismetrep: A Novel Approach for Treating Migraine,” at the 2026 American Academy of Neurology (AAN) Annual Meeting.
Migraine Epidemiology Segmentation
The migraine epidemiology section provides insights into the historical and current migraine patient pool and forecasted trends for the leading markets. In the United States, the acute migraine severity distribution in 2025 was estimated at 16 million, 7 million, 8 million, and 14 million for MIDAS Grade I, Grade II, Grade III, and Grade IV, respectively.
The migraine market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets segmented into:
- Migraine Prevalent Cases
- Migraine Prevalent Cases by Gender
- Acute and Chronic Migraine Prevalent Cases
- Menstrual Migraine Prevalent Cases
- Migraine Prevalent Cases by Severity (MIDAS Grading)
- Chronic/Episodic Migraine Receiving Treatments
- Chronic/Episodic Migraine Receiving Preventive Treatments
Download the report to understand the CGRP migraine medications @ Migraine Headache Drugs Market
| Migraine Market Report Metrics | Details |
| Study Period | 2022–2036 |
| Migraine Market Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Migraine Market CAGR (2022–2036) | 6% |
| Migraine Market Size in 2025 | USD 8.3 Billion |
| Key Migraine Companies | Kallyope, Ipsen, Merz Therapeutics GmbH, Lundbeck, Evommune, Impel Pharmaceuticals, Satsuma Pharmaceuticals, Amneal Pharmaceuticals, Axsome Therapeutics, Currax Pharmaceuticals, Tonix Pharmaceuticals, Dr. Reddy’s Laboratories, Allergan, Scilex Holding, Pfizer, Biohaven, Gensco Pharma, IntelGenx, Amgen, Novartis, Teva Pharmaceuticals, Eli Lilly, Allergan, AbbVie, and others |
| Key Migraine Therapies | Elismetrep, Dysport (abobotulinumtoxinA), Xeomin (incobotulinumtoxinA), Bocunebart (AG09222), EVO756, TRUDHESA/INP104, ATZUMI, BREKIYA, SYMBRAVO, ZEMBRACE SYMTOUCH, ONZETRA XSAIL, AVP-825, TOSYMRA, UBRELVY, NURTEC ODT/VYDURA, ELYXYB, ZAVZPRET, RIZAPORT, AQUIPTA/QULIPTA, AIMOVIG, AJOVY, EMGALITY, VYEPTI, BOTOX, and others |
Scope of the Migraine Market Report
- Migraine Patient Population Forecast
- Migraine Therapeutics Market Size
- Migraine Pipeline Analysis
- Migraine Market Size and Trends
- Migraine Market Opportunity
- Migraine Market Unmet Needs
- KOL’s Views on Migraine
- Migraine Market Access and Reimbursement
Frequently Asked Questions from the Migraine Market Report
- How is AI transforming the migraine clinical trial landscape and competitive intelligence?
- Which pharmaceutical companies and investigational therapies are leading the development of next-generation migraine treatments?
- How do emerging migraine therapies compare in clinical efficacy, safety, tolerability, and their potential to reduce the frequency and severity of migraine attacks?
- Which novel mechanisms of action, including TRPM8 blockers, PACAP-targeted therapies, MRGPRX2 antagonists, and next-generation neuromuscular approaches, could reshape the future of migraine treatment?
- How can AI identify emerging clinical trial trends, competitor milestones, regulatory developments, and potential market disruptions in the migraine therapeutics landscape?
- Where are the most significant unmet needs and opportunities for differentiation in acute and preventive migraine treatment?
- How can AI-driven insights help pharmaceutical companies make smarter clinical development, investment, licensing, and strategic partnering decisions in the migraine market?
Discover more about next-generation migraine drugs @ Migraine Clinical Trials
Table of Contents
| 1 | Migraine Market Key Insights |
| 2 | Migraine Market Report Introduction |
| 3 | Executive Summary of Migraine |
| 4 | Key Events |
| 5 | Epidemiology and Market Forecast Methodology |
| 6 | Migraine Market Overview at a Glance |
| 6.1 | Emerging Landscape Analysis (by Mechanism of Action (MoA), Phase, and Route of Administration [RoA]) |
| 6.2 | Market Share (%) Distribution of Migraine by Class of Therapies in the 7MM in 2025 |
| 6.3 | Market Share (%) Distribution of Migraine by Class of Therapies in the 7MM in 2036 |
| 7 | Disease Background and Overview |
| 7.1 | Introduction |
| 7.2 | Signs and Symptoms |
| 7.3 | Risk Factors |
| 7.4 | Causes |
| 8 | Current Treatment Practices: Migraine |
| 8.1 | Treatment Algorithm |
| 8.2 | Treatment Guidelines and Recommendations for Migraine |
| 9 | Epidemiology and Patient Population of 7MM |
| 9.1 | Key Findings |
| 9.2 | Assumptions and Rationale |
| 9.3 | Migraine Prevalent Cases in the 7MM |
| 9.4 | The United States |
| 9.4.1 | Migraine Prevalent Cases in the United States |
| 9.4.2 | Migraine Prevalent Cases by Gender in the United States |
| 9.4.3 | Acute and Chronic Migraine Prevalent Cases in the United States |
| 9.4.4 | Menstrual Migraine Prevalent Cases in the United States |
| 9.4.5 | Migraine Prevalent Cases by Severity (MIDAS Grading) in the United States |
| 9.4.5.1 | Acute Migraine Prevalent Cases by Severity in the United States |
| 9.4.5.2 | Chronic Migraine Prevalent Cases by Severity in the United States |
| 9.4.6 | Chronic/Episodic Migraine Receiving Treatments in the United States |
| 9.4.7 | Chronic/Episodic Migraine Receiving Preventive Treatments in the United States |
| 9.5 | EU4 and the UK |
| 9.6 | Japan |
| 10 | Patient Journey |
| 11 | Marketed Therapies |
| 11.1 | Marketed Drugs Competitive Landscape |
| 11.2 | Dihydroergotamine mesylate (TRUDHESA/INP104): Impel Pharmaceuticals |
| 11.2.1 | Product Description |
| 11.2.2 | Regulatory Milestones |
| 11.2.3 | Other Developmental Activities |
| 11.2.4 | Summary of Pivotal Trial |
| 11.2.5 | Safety and Efficacy |
| 11.2.6 | Analyst Views |
| 11.3 | Dihydroergotamine/STS101 (ATZUMI): Satsuma Pharmaceuticals |
| 11.4 | Dihydroergotamine mesylate (BREKIYA): Amneal Pharmaceuticals |
| 11.5 | Meloxicam and rizatriptan (SYMBRAVO): Axsome Therapeutics |
| 11.6 | Sumatriptan (ZEMBRACE SYMTOUCH): Tonix Pharmaceuticals |
| 11.7 | Sumatriptan (ONZETRA XSAIL, AVP-825): Currax Pharmaceuticals |
| 11.8 | Sumatriptan (TOSYMRA): Tonix Pharmaceuticals/Dr. Reddy’s Laboratories |
| 11.9 | Ubrogepant (UBRELVY): AbbVie/Allergan |
| 11.10 | Rimegepant (NURTEC ODT/VYDURA): Pfizer/Biohaven |
| 11.11 | Celecoxib (ELYXYB): Scilex Holding |
| 11.12 | Zavegepant (ZAVZPRET, PF-07930207): Pfizer/Biohaven |
| 11.13 | Rizatriptan (RIZAPORT): Gensco Pharma/IntelGenx |
| 11.14 | Atogepant (AQUIPTA, QULIPTA): AbbVie |
| 11.15 | Erenumab (AIMOVIG): Amgen/Novartis |
| 11.16 | Fremanezumab (AJOVY): Teva Pharmaceuticals |
| 11.17 | Galcanezumab (EMGALITY): Eli Lilly |
| 11.18 | Eptinezumab (VYEPTI): Lundbeck |
| 11.19 | OnabotulinumtoxinA (BOTOX): Allergan / AbbVie |
| 12 | Emerging Therapies |
| 12.1 | Emerging Competitive Landscape |
| 12.2 | Elismetrep: Kallyope |
| 12.2.1 | Product Description |
| 12.2.2 | Other Developmental Activities |
| 12.2.3 | Clinical Development |
| 12.2.3.1 | Clinical Trial Information |
| 12.2.4 | Safety and Efficacy |
| 12.2.5 | Analyst Views |
| 12.3 | Dysport (abobotulinumtoxinA): Ipsen |
| 12.4 | Xeomin (incobotulinumtoxinA): Merz Therapeutics GmBH |
| 12.5 | Bocunebart (AG09222): Lundbeck |
| 12.6 | EVO756: Evommune |
| 13 | Migraine Market: The 7MM Analysis |
| 13.1 | Key Findings |
| 13.2 | Migraine Market Outlook |
| 13.2.1 | Acute Migraine Treatment |
| 13.2.2 | Preventive Migraine Treatment |
| 13.3 | Conjoint Analysis |
| 13.4 | Key Market Forecast Assumptions |
| 13.5 | Total Market Size of Migraine in the 7MM |
| 13.6 | Market Size of Migraine by Therapies in the 7MM |
| 13.7 | The United States Migraine Market |
| 13.7.1 | Total Market Size of Migraine in the United States |
| 13.7.2 | Market Size of Migraine by Therapies in the United States |
| 13.8 | EU4 and the UK Migraine Market |
| 13.9 | Japan Migraine Market |
| 14 | Unmet Needs |
| 15 | SWOT Analysis |
| 16 | KOL Views |
| 17 | Market Access and Reimbursement |
| 17.1 | The United States |
| 17.2 | EU4 and the UK |
| 17.2.6 | Japan |
| 17.3 | Summary and Comparison of Market Access and Pricing Policy Developments in 2025 |
| 17.4 | Market Access and Reimbursement of Migraine |
| 18 | Bibliography |
| 19 | Migraine Market Report Methodology |
Related Reports
Migraine Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key migraine companies, including Merz Pharma, H. Lundbeck A/S, Biohaven Therapeutics Ltd., 4E Therapeutics, Evoimmune, Inc., Ceruvia Lifesciences, Ipsen Pharma, Aspeya, Inc., Kallyope Inc., Mentari Therapeutics, InMed Pharmaceuticals, and others.
CGRP Inhibitors in Migraine Competitive Landscape – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CGRP inhibitors in migraine companies, including Pfizer, H. Lundbeck A/S, Eli Lilly and Company, Tonix Pharmaceuticals Holding Corp, and others.
Digital Migraine Treatment Devices Market Insights, Competitive Landscape, and Market Forecast – 2034 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key digital migraine treatment devices companies including CEFALY Technology, Theranica Bio-Electronics, electroCore, Inc., Neurolief Ltd., eNeura, Inc., WAT Medical Technology, Soterix Medical, Inc., Nu Eyne Co., Ltd., Ybrain, Inc., and Shenzhen Dongdixin Technology Co., Ltd., and others.
Cluster Headache Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key cluster headache companies, including Novartis AG, Zosano Pharma, Eli Lily and Company, AstraZeneca Plc., Autonomic Technologies, Inc., ElectroCore Medical LLC, GlaxoSmithKline Plc, Winston Pharmaceuticals Inc., Lundbeck Seattle BioPharmaceutical, and others.
Cluster Headache Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key cluster headache companies, including Novartis AG, Zosano Pharma, Eli Lily and Company, AstraZeneca Plc., Autonomic Technologies, Inc., ElectroCore Medical LLC, GlaxoSmithKline Plc, Winston Pharmaceuticals Inc., Lundbeck Seattle BioPharmaceutical, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
CONTACT: Contact Us Shruti Thakur info@delveinsight.com +14699457679
Comments (0)
Login to join the conversation
Login / RegisterNo comments yet. Be the first to comment!